This company has been marked as potentially delisted and may not be actively trading. GX Acquisition (GXGX) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsTrendsBuy This Stock GXGX vs. AVTE, NLTX, BIOA, CYBN, VIRI, WHWK, OSTX, ELYM, ATNM, and NBRVShould you be buying GX Acquisition stock or one of its competitors? The main competitors of GX Acquisition include Aerovate Therapeutics (AVTE), Neoleukin Therapeutics (NLTX), BioAge Labs (BIOA), Cybin (CYBN), Virios Therapeutics (VIRI), Whitehawk Therapeutics (WHWK), OS Therapies (OSTX), Eliem Therapeutics (ELYM), Actinium Pharmaceuticals (ATNM), and Nabriva Therapeutics (NBRV). GX Acquisition vs. Its Competitors Aerovate Therapeutics Neoleukin Therapeutics BioAge Labs Cybin Virios Therapeutics Whitehawk Therapeutics OS Therapies Eliem Therapeutics Actinium Pharmaceuticals Nabriva Therapeutics Aerovate Therapeutics (NASDAQ:AVTE) and GX Acquisition (NASDAQ:GXGX) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their dividends, profitability, institutional ownership, earnings, media sentiment, valuation, risk and analyst recommendations. Is AVTE or GXGX more profitable? Aerovate Therapeutics' return on equity of -90.19% beat GX Acquisition's return on equity.Company Net Margins Return on Equity Return on Assets Aerovate TherapeuticsN/A -90.19% -77.47% GX Acquisition N/A -985.20%-6.02% Do insiders & institutionals have more ownership in AVTE or GXGX? 61.7% of GX Acquisition shares are held by institutional investors. 24.9% of Aerovate Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term. Does the media favor AVTE or GXGX? In the previous week, Aerovate Therapeutics had 2 more articles in the media than GX Acquisition. MarketBeat recorded 2 mentions for Aerovate Therapeutics and 0 mentions for GX Acquisition. Aerovate Therapeutics' average media sentiment score of 1.68 beat GX Acquisition's score of 0.00 indicating that Aerovate Therapeutics is being referred to more favorably in the media. Company Overall Sentiment Aerovate Therapeutics Very Positive GX Acquisition Neutral Which has more risk and volatility, AVTE or GXGX? Aerovate Therapeutics has a beta of 0.95, indicating that its stock price is 5% less volatile than the S&P 500. Comparatively, GX Acquisition has a beta of 0.17, indicating that its stock price is 83% less volatile than the S&P 500. Which has stronger valuation and earnings, AVTE or GXGX? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAerovate TherapeuticsN/AN/A-$75.52M-$1.70-4.53GX AcquisitionN/AN/A-$49.26MN/AN/A SummaryAerovate Therapeutics beats GX Acquisition on 5 of the 8 factors compared between the two stocks. Get GX Acquisition News Delivered to You Automatically Sign up to receive the latest news and ratings for GXGX and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding GXGX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart GXGX vs. The Competition Export to ExcelMetricGX AcquisitionPharmaceutical Preparations IndustryMedical SectorNASDAQ ExchangeMarket Cap$83.37M$833.26M$5.75B$10.24BDividend YieldN/A4.84%5.69%4.60%P/E RatioN/A1.1874.9326.41Price / SalesN/A121.58452.3586.56Price / CashN/A19.5625.8129.91Price / Book16.576.6613.256.28Net Income-$49.26M-$4.13M$3.29B$270.38M GX Acquisition Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)GXGXGX AcquisitionN/A$2.32-0.4%N/A-17.1%$83.37MN/A0.00N/AAVTEAerovate TherapeuticsN/A$7.62-3.5%N/A-88.4%$220.87MN/A-2.5520Positive NewsHigh Trading VolumeNLTXNeoleukin TherapeuticsN/A$19.64+6.3%N/A-54.7%$184.58MN/A-6.3290BIOABioAge Labs0.2001 of 5 stars$4.74+1.9%N/AN/A$176.74MN/A0.00N/ACYBNCybin2.694 of 5 stars$6.01-3.7%$85.00+1,314.3%N/A$141.78MN/A-1.3750Gap DownHigh Trading VolumeVIRIVirios TherapeuticsN/A$4.81-3.0%$5.00+3.9%+2,409.0%$92.63MN/A-17.825WHWKWhitehawk Therapeutics1.1838 of 5 stars$1.81-0.5%N/AN/A$85.07M$25.98M-30.1740OSTXOS Therapies2.0734 of 5 stars$2.10-5.4%$18.00+757.1%-34.6%$66.45MN/A-2.66N/AAnalyst ForecastELYMEliem TherapeuticsN/A$2.23flatN/A-73.4%$66.35MN/A-4.219News CoverageATNMActinium Pharmaceuticals2.2131 of 5 stars$1.71-1.2%$4.50+163.2%-12.4%$53.35MN/A-1.2330NBRVNabriva TherapeuticsN/AN/AN/AN/A$45.46M$35.59M0.0070 Related Companies and Tools Related Companies AVTE Competitors NLTX Competitors BIOA Competitors CYBN Competitors VIRI Competitors WHWK Competitors OSTX Competitors ELYM Competitors ATNM Competitors NBRV Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:GXGX) was last updated on 9/15/2025 by MarketBeat.com Staff From Our PartnersHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredWhy Trump’s “Smart Dollar” could rewrite the rulesMUST SEE: Donald Trump's Radical Overhaul of the U.S. Dollar Congress just approved President Trump's lates...Stansberry Research | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredTrump's Law S.1582: $21T Dollar Revolution ComingDo you have money in any of these banks? Chase. Bank of America. Citigroup. Wells Fargo. U.S. Bancorp. I...Brownstone Research | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredStrange crypto pattern discovered by 40-person research teamSomething unusual is happening inside a 40-person crypto research firm. They're helping 8,000+ ordinary peo...Crypto Swap Profits | SponsoredRetire Comfortably with These New Monthly Income ETFs?Too many retirees lie awake at night, worried their savings won’t last. Traditional advice and tiny returns ju...Investors Alley | SponsoredNvidia Times 1,000,000Nvidia’s latest AI chip is a $25,000 powerhouse — with 80 billion transistors and the ability to perform 60 tr...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding GX Acquisition Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share GX Acquisition With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free GXGX Stock Alerts